Avectas
Dr. Ann Brady is the Chief Business Officer and Board Member at Avectas since 2016. Previously served as President at Theravance Biopharma US, Inc. from 2016 to 2022 and held various leadership roles at Shire Pharmaceuticals, including Vice President of Alliance Management & New Market Development and Vice President of New Market Development. Prior experience includes Vice President of Global Supply Chain & Strategic Sourcing at Elan Pharmaceuticals and Vice President of Corporate Development and Director of Business Development at the same company. Dr. Brady's academic qualifications include a PhD in Chemistry from Trinity College Dublin, CDir from the Institute of Directors, and a BA(Mod) in Natural Sciences from Trinity College Dublin, along with a CDipAF from ACCA.
This person is not in any offices
Avectas
1 followers
Avectas is a cell engineering business focused on improving the cost, manufacturing, and patient outcomes for the next generation of cellular therapies. Avectas is developing a unique delivery technology platform, Solupore®, to enable the ex-vivo manufacture of gene-modified cell therapy products, with partners.